Quote:

---

Compared with participants receiving placebo, those getting 350 mg of leronlimab weekly also had significant drops in ALT, AST, alkaline phosphatase and multiple markers of inflammation: VCAM, CCL2, CCL3, CCL5, CCL18, interferon gamma, IL-6, IL-8, IL-1 receptor antagonist. TNF receptor 2, and tissue inhibitor of MMP-1 and EN RAGE.
https://www.natap.org/2022/EASL/EASL_70.htm

---